Your browser doesn't support javascript.
loading
Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.
Xie, Huafeng; Peng, Cong; Huang, Jialiang; Li, Bin E; Kim, Woojin; Smith, Elenoe C; Fujiwara, Yuko; Qi, Jun; Cheloni, Giulia; Das, Partha P; Nguyen, Minh; Li, Shaoguang; Bradner, James E; Orkin, Stuart H.
Afiliação
  • Xie H; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Peng C; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Huang J; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Li BE; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Heath, Boston, Massachusetts.
  • Kim W; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Smith EC; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Fujiwara Y; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Qi J; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Cheloni G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Das PP; Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
  • Nguyen M; Department of Experimental and Clinical Biomedical Sciences "Mario Serio," University of Florence, Florence, Italy.
  • Li S; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Bradner JE; Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts.
  • Orkin SH; Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Cancer Discov ; 6(11): 1237-1247, 2016 11.
Article em En | MEDLINE | ID: mdl-27630126
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Complexo Repressor Polycomb 2 / Proteína Potenciadora do Homólogo 2 de Zeste Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2016 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Complexo Repressor Polycomb 2 / Proteína Potenciadora do Homólogo 2 de Zeste Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2016 Tipo de documento: Article País de publicação: Estados Unidos